rabeprazole has been researched along with Esophagitis, Peptic in 60 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Esophagitis, Peptic: INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 9.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 9.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 9.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 6.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| "Erosive gastro-oesophageal reflux disease (GERD) is a chronic condition requiring long-term maintenance treatment." | 6.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 5.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| "Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks." | 5.15 | Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G ( Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011) |
| "To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)." | 5.15 | Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011) |
| "In patients with endoscopy-confirmed erosive esophagitis treated with once-daily rabeprazole 20 mg, prompt and continuing improvements were seen in daytime and nighttime heartburn, belching, regurgitation, and dysphagia." | 5.14 | Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. ( Cutler, A; Delemos, B; Murthy, A; Robinson, M, 2010) |
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 5.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "This study aimed to determine whether dysphagia associated with gastroesophageal reflux disease was effectively treated with rabeprazole, a proton pump inhibitor." | 5.11 | Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. ( Danjo, A; Fujimoto, K; Hara, M; Iwakiri, R; Kikkawa, A; Oda, K; Ootani, A; Sakata, H; Shimoda, R; Tsunada, S; Watanabe, K, 2005) |
| " Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD)." | 5.10 | Integrated acidity and rabeprazole pharmacology. ( Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S, 2002) |
| "The mean heartburn score in patients administered rabeprazole decreased more rapidly than those given the other PPI." | 5.10 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003) |
| "On day 1, rabeprazole significantly decreased daytime and night-time heartburn severity, regurgitation and belching." | 5.10 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 5.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| "To determine if patients with gastro-oesophageal reflux disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, could be maintained on rabeprazole 20 mg once daily." | 3.74 | Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. ( Coté, GA; Ferreira, MR; Howden, CW; Rozenberg-Ben-Dror, K, 2007) |
| " For the rate of adverse events, there was no significant difference among all the PPIs, vonoprazan, and placebo." | 2.82 | Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. ( Chen, J; Deng, W; Xie, Z; Yang, S, 2022) |
| " dosing is often used in refractory RE (rRE) patients, although there has been no report of endoscopically confirmed healing with b." | 2.77 | Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. ( Hongo, M; Kinoshita, Y, 2012) |
| " We performed serial endoscopy, checked gastroesophageal reflux disease (GERD) symptoms, adverse events, laboratory values and serum gastrin." | 2.76 | Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. ( Fujimoto, K; Hongo, M, 2011) |
| " Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day." | 2.75 | Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010) |
| "Rabeprazole is an effective and well-tolerated drug for GERD treatment." | 2.72 | [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis]. ( Baek, JT; Chung, IK; Jeong, HY; Kim, AN; Kim, SH; Kim, SJ; Lee, BS; Lee, DS; Lee, GS; Lee, JM; Lee, SH; Lee, TY; Nam, SW; Oh, JI; Shin, JE; Sung, JK; Yoon, SJ, 2006) |
| "Erosive gastro-oesophageal reflux disease (GERD) is a chronic condition requiring long-term maintenance treatment." | 2.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 2.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| "Reflux esophagitis is a recurring condition for which many patients require maintenance therapy." | 2.71 | [A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study]. ( Han, SY; Jee, SR; Kim, DH; Lee, JT; Park, SJ; Seol, SY; Urm, SH, 2005) |
| "Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD." | 2.69 | Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. ( Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B, 2000) |
| "Rabeprazole was well-tolerated in this short-term study." | 2.68 | Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. ( Greenwood, B; Humphries, TJ; Maton, PN; Robinson, M; Rodriguez, S, 1997) |
| "Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD)." | 2.53 | The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. ( Chen, L; Chen, Y; Li, B, 2016) |
| "Whether these patients are part of the GERD spectrum or have another diagnosis is not clear." | 2.43 | Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006) |
| "The rabeprazole dose was determined by the attending physician." | 1.46 | Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. ( Furuhata, Y; Hongo, M; Ikeuchi, S; Kinoshita, Y; Kusano, M; Miyagishi, H, 2017) |
| "A total of 5,279 GERD patients with Frequency Scale for the Symptoms of GERD (FSSG) scores ≥ 8 points at baseline were analyzed." | 1.38 | Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. ( Hongo, M; Kusano, M; Miwa, H, 2012) |
| "PCS score improved in underweight patients." | 1.38 | Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors. ( Hongo, M; Kusano, M; Miwa, H, 2012) |
| "Treatment with Rabeprazole helps efficiently jugulate reflux disease symptoms and accurately improve quality of life index." | 1.35 | [The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy]. ( Golubev, NN; Iablunovskaia, GI; Maev, IV; Odintsova, AN; Samsonov, AA, 2009) |
| "The scale of GERD-HRQL decreased significantly in RE patients than in NERD patients." | 1.33 | [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease]. ( Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Sun, J; Yuan, YZ; Zha, H; Zhu, YL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 33 (55.00) | 29.6817 |
| 2010's | 24 (40.00) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, C | 1 |
| Wu, X | 1 |
| Pu, Z | 1 |
| Chen, D | 1 |
| Pu, Y | 1 |
| Peng, A | 1 |
| Yang, S | 3 |
| Deng, W | 3 |
| Xie, Z | 3 |
| Chen, J | 3 |
| Kinoshita, Y | 7 |
| Hongo, M | 10 |
| Kusano, M | 7 |
| Furuhata, Y | 1 |
| Miyagishi, H | 1 |
| Ikeuchi, S | 1 |
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Kato, M | 1 |
| Fujishiro, M | 1 |
| Masuyama, H | 1 |
| Nakata, R | 1 |
| Abe, H | 1 |
| Kumagai, S | 1 |
| Fukushima, Y | 1 |
| Okubo, Y | 1 |
| Hojo, S | 1 |
| Huo, X | 1 |
| Souza, RF | 1 |
| Haddad, I | 1 |
| Kierkus, J | 1 |
| Tron, E | 1 |
| Ulmer, A | 1 |
| Hu, P | 1 |
| Sloan, S | 3 |
| Silber, S | 1 |
| Leitz, G | 1 |
| Nagahara, A | 2 |
| Suzuki, T | 1 |
| Nagata, N | 1 |
| Sugai, N | 1 |
| Takeuchi, Y | 1 |
| Sakurai, K | 1 |
| Miyamoto, M | 1 |
| Inoue, K | 1 |
| Akiyama, J | 1 |
| Mabe, K | 1 |
| Konuma, I | 1 |
| Kamada, T | 1 |
| Haruma, K | 1 |
| Akahoshi, T | 1 |
| Kawanaka, H | 1 |
| Tomikawa, M | 1 |
| Saeki, H | 1 |
| Uchiyama, H | 1 |
| Ikeda, T | 1 |
| Shirabe, K | 1 |
| Hashizume, M | 1 |
| Maehara, Y | 1 |
| Takeuchi, T | 1 |
| Oota, K | 1 |
| Harada, S | 1 |
| Edogawa, S | 1 |
| Kojima, Y | 1 |
| Sanomura, M | 1 |
| Sakaguchi, M | 1 |
| Hayashi, K | 1 |
| Hongoh, Y | 1 |
| Itabashi, T | 1 |
| Kitae, H | 1 |
| Hoshimoto, M | 1 |
| Takeuchi, N | 1 |
| Higuchi, K | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Li, B | 1 |
| Sarosiek, I | 1 |
| Olyaee, M | 1 |
| Majewski, M | 1 |
| Sidorenko, E | 1 |
| Roeser, K | 1 |
| Sostarich, S | 1 |
| Wallner, G | 1 |
| Sarosiek, J | 1 |
| Cutler, A | 1 |
| Robinson, M | 4 |
| Murthy, A | 2 |
| Delemos, B | 2 |
| Sugimoto, M | 2 |
| Nishino, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Ikuma, M | 1 |
| Tanaka, T | 1 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Furuta, T | 3 |
| Maev, IV | 1 |
| Samsonov, AA | 1 |
| Odintsova, AN | 1 |
| Golubev, NN | 1 |
| Iablunovskaia, GI | 1 |
| Fujimoto, K | 3 |
| Tan, VP | 1 |
| Wong, BC | 1 |
| Miwa, H | 5 |
| Oguro, M | 1 |
| Koike, M | 1 |
| Ueno, T | 1 |
| Asaoka, D | 1 |
| Mori, H | 1 |
| Uchiyama, Y | 1 |
| Watanabe, S | 1 |
| Shimatani, T | 2 |
| Ishihara, S | 1 |
| Fujiwara, Y | 1 |
| Koike, T | 2 |
| Chiba, T | 2 |
| Pace, F | 2 |
| Coudsy, B | 1 |
| Sun, Y | 1 |
| Xiang, J | 1 |
| LoCoco, J | 1 |
| Casalini, S | 2 |
| Li, H | 1 |
| Pelosini, I | 1 |
| Scarpignato, C | 1 |
| Fass, R | 1 |
| Takubo, K | 1 |
| Oshima, T | 1 |
| Tanaka, J | 1 |
| Aida, J | 1 |
| Ito, M | 1 |
| Kurosawa, S | 1 |
| Joh, T | 1 |
| Wada, T | 1 |
| Habu, Y | 1 |
| Watanabe, Y | 1 |
| Osadchuk, MA | 2 |
| Lipatova, TE | 2 |
| Chaplygin, NV | 2 |
| Arutiunov, AG | 1 |
| Burkov, SG | 1 |
| Burdina, EG | 1 |
| Svirchev, VV | 1 |
| Damiano, A | 1 |
| Siddique, R | 1 |
| Xu, X | 1 |
| Johanson, J | 1 |
| Adachi, K | 2 |
| Hashimoto, T | 1 |
| Hamamoto, N | 1 |
| Hirakawa, K | 1 |
| Niigaki, M | 1 |
| Miyake, T | 1 |
| Taniura, H | 1 |
| Ono, M | 1 |
| Kaji, T | 1 |
| Suetsugu, H | 1 |
| Yagi, J | 1 |
| Komazawa, Y | 1 |
| Mihara, T | 1 |
| Katsube, T | 1 |
| Fujishiro, H | 1 |
| Shizuku, T | 1 |
| Hattori, S | 1 |
| Yamamoto, S | 1 |
| Swiatkowski, M | 1 |
| Budzyński, J | 1 |
| Kłopocka, M | 1 |
| Grad, K | 1 |
| Pulkowski, G | 1 |
| Augustyńska, B | 1 |
| Suppan, K | 1 |
| Fabisiak, J | 1 |
| Jee, SR | 1 |
| Seol, SY | 1 |
| Kim, DH | 1 |
| Park, SJ | 1 |
| Han, SY | 1 |
| Urm, SH | 1 |
| Lee, JT | 1 |
| Annese, V | 1 |
| Prada, A | 1 |
| Zambelli, A | 1 |
| Nardini, P | 1 |
| Bianchi Porro, G | 1 |
| Caos, A | 2 |
| Breiter, J | 1 |
| Perdomo, C | 3 |
| Barth, J | 2 |
| Oda, K | 1 |
| Iwakiri, R | 1 |
| Hara, M | 1 |
| Watanabe, K | 1 |
| Danjo, A | 1 |
| Shimoda, R | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Sakata, H | 1 |
| Tsunada, S | 1 |
| Liu, XH | 1 |
| Ke, MY | 1 |
| Song, ZQ | 1 |
| Luo, JY | 1 |
| Yuan, YZ | 1 |
| Hou, XH | 1 |
| Zhu, YL | 1 |
| Sun, J | 1 |
| Zha, H | 1 |
| Jeong, HY | 1 |
| Lee, BS | 1 |
| Sung, JK | 1 |
| Lee, TY | 1 |
| Yoon, SJ | 2 |
| Kim, SJ | 1 |
| Chung, IK | 1 |
| Lee, SH | 1 |
| Shin, JE | 1 |
| Lee, DS | 1 |
| Baek, JT | 1 |
| Nam, SW | 1 |
| Kim, SH | 1 |
| Lee, GS | 1 |
| Lee, JM | 1 |
| Kim, AN | 1 |
| Oh, JI | 1 |
| DeVault, KR | 1 |
| Ariizumi, K | 1 |
| Ohara, S | 1 |
| Inomata, Y | 1 |
| Iijima, K | 1 |
| Sekine, H | 1 |
| Noguchi, M | 1 |
| Sugiyama, K | 1 |
| Eda, Y | 1 |
| Kayaba, S | 1 |
| Kawamura, M | 1 |
| Shimosegawa, T | 1 |
| Edwards, SJ | 1 |
| Lind, T | 1 |
| Lundell, L | 1 |
| Coté, GA | 1 |
| Ferreira, MR | 1 |
| Rozenberg-Ben-Dror, K | 1 |
| Howden, CW | 1 |
| Tanaka, K | 1 |
| Toyoda, H | 1 |
| Kadowaki, S | 1 |
| Hamada, Y | 1 |
| Kosaka, R | 1 |
| Yamanaka, M | 1 |
| Imoto, I | 1 |
| Lee, YC | 1 |
| Lin, JT | 1 |
| Wang, HP | 1 |
| Chiu, HM | 1 |
| Wu, MS | 1 |
| Nakamura, H | 1 |
| Nakaji, G | 1 |
| Shimazu, H | 1 |
| Yasuda, S | 1 |
| Odashiro, K | 1 |
| Maruyama, T | 1 |
| Kaji, Y | 1 |
| Chishaki, A | 1 |
| Maton, PN | 1 |
| Rodriguez, S | 1 |
| Greenwood, B | 1 |
| Humphries, TJ | 2 |
| Thjodleifsson, B | 1 |
| Beker, JA | 1 |
| Dekkers, C | 1 |
| Bjaaland, T | 1 |
| Finnegan, V | 1 |
| Moskovitz, M | 1 |
| Dayal, Y | 1 |
| Niecestro, R | 1 |
| Ofman, JJ | 2 |
| Yamashita, BD | 2 |
| Siddique, RM | 2 |
| Larson, LR | 1 |
| Willian, MK | 1 |
| Gregor, JC | 1 |
| Bardou, M | 1 |
| Dean, BB | 1 |
| Bhattacharjya, AS | 1 |
| Fitzgerald, S | 1 |
| Hegedus, R | 1 |
| Jokubaitis, L | 1 |
| Gardner, JD | 1 |
| Hahne, WF | 1 |
| Barth, JA | 1 |
| Rodriguez-Stanley, S | 1 |
| Takahashi, M | 1 |
| Kuwayama, H | 1 |
| Ivanova, NG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis[NCT01321567] | 2,157 participants (Actual) | Observational | 2011-01-01 | Completed | |||
| A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients[NCT02135107] | Phase 3 | 517 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891] | Phase 3 | 127 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Non-recurrence rate at Week 52 was estimated using the Kaplan-Meier method. (NCT02135107)
Timeframe: Week 52
| Intervention | Percentage of non-recurrence (Number) |
|---|---|
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 41.5 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 71.4 |
A comparison of rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group shall be performed for participants who did not exhibit daytime or nighttime heartburn at 0 weeks of the maintenance therapy period. Daytime and nighttime heartburn, and nighttime sleep disorders shall likewise be compared. For the participants who had recurrence, values at the final evaluation were imputed using a last observation carried forward (LOCF) method. (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 0 Days (no symptoms) | 1 to 2 Days (occasional symptoms) | 3 to 4 Days (sometimes had symptoms) | 5 to 6 Days (often had symptoms) | 7 Days (always had symptoms) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 85.2 | 12.3 | 1.9 | 0.0 | 0.6 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 85.1 | 11.2 | 0.6 | 1.9 | 1.2 |
Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). Heartburn was evaluated prior to 7 days of each visit. (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 0 Day (none) | 1 to 2 Days (occasional symptoms) | 3 to 4 Days (sometimes had symptoms) | 5 to 6 Days (often had symptoms) | 7 Days (always had symptoms) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 96.9 | 2.5 | 0.6 | 0.0 | 0.0 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 98.1 | 0.6 | 0.0 | 0.6 | 0.6 |
Safety was assessed by monitoring and recording all adverse events (AEs) and SAEs, regular monitoring of hematology, clinical chemistry, urine values, and regular measurement of vital signs. All AEs were graded on a 3-point scale; 1) mild was defined as discomfort that did not interfere with normal daily activities, 2) moderate was defined as discomfort that interfered with normal activities, and 3) severe was defined as discomfort that interfered with the ability to work or normal daily activities were impossible. SAEs were medical events that led to death, were life-threatening, required hospitalization or prolongation of hospitalization, caused persistent disability, or resulted in a congenital abnormality. TEAEs were AEs with an onset date on or after the first dose of study drug and up to 30 days after receiving the last dose of study drug. Treatment-related AEs were medical events that were considered by the investigator to be possibly or probably related to rabeprazole. (NCT02135107)
Timeframe: From date of first dose up to 30 days after the last dose of study drug, up to approximately 1 year 3 months (Treatment Period; 8 weeks, Maintenance Therapy Period; 52 weeks, and Follow-up Period; 30 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| TEAEs | Treatment-related TEAEs | Severe TEAEs | Serious TEAEs | |
| Rabeprazole: 10 mg Twice Daily | 111 | 20 | 2 | 6 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once daiArm C | 111 | 7 | 4 | 11 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 125 | 11 | 3 | 17 |
| Rabeprazole: 20 mg Twice Daily | 21 | 1 | 1 | 4 |
A comparison of the rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. Heartburn is a burning sensation in the stomach or lower chest; it is worsened by bending or pressure on the abdomen. Heartburn frequency was rated from 0-day (no) to 7-day (always) and severity was graded on a 3-point scale (mild, moderate, severe). Heartburn was evaluated in the daytime (from wake-up time to time for bed) and nighttime (from time for bed to wake-up time). (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Heartburn (yes) | Heartburn (no) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 23.2 | 76.8 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 8.0 | 92.0 |
"Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Sleep disorders during each of the 7-day periods immediately before visiting the hospital were assessed. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). The incidence of sleep disorder was tabulated by an analysis classifying the stages into two groups: No (0 days with sleep disorder) and Yes (1 or more days with sleep disorder). Heartburn was evaluated prior to 7 days of each visit." (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Sleep disorders from heartburn/acid reflux (yes) | Sleep disorders from heartburn/acid reflux (no) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 2.5 | 97.5 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 2.5 | 97.5 |
The non-recurrence rate (at 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. (NCT02135107)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Non-recurrence | Recurrence | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 44.8 | 55.2 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 73.9 | 26.1 |
The non-recurrence rate (up to 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. The 95% CI was calculated by normal approximation. (NCT02135107)
Timeframe: Weeks 12 and 24
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 12, Non-recurrence | Week 12, Recurrence | Week 24, Non-recurrence | Week 24, Recurrence | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 62.5 | 37.5 | 55.8 | 44.2 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 92.4 | 7.6 | 85.1 | 14.9 |
"A comparison of the rabeprazole (10 mg once daily group) and the rabeprazole (10 mg twice daily group) was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. The presence or absence of heartburn was assessed by the investigators during medical interviews. The heartburn incidence during each of the 7-day periods immediately before visiting the hospital was assessed on a scale of five stages based on the number of days with symptoms: 0 (no symptoms), 1 to 2 (occasional symptoms), 3 to 4 (sometimes had symptoms), 5 to 6 (often had symptoms), and 7 (always had symptoms). The incidence was tabulated by an analysis classifying the states into two groups: no symptom group (0 days with symptoms) and with symptoms group (1 day or more with symptoms). The severity of heartburn was as below: Mild (feel heartburn but tolerable), Moderate (feel heartburn and hard), and Severe (feel heartburn and terrible)." (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| None | Mild | Moderate | Severe | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 85.2 | 14.8 | 0.0 | 0.0 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 85.1 | 14.3 | 0.6 | 0.0 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 0.2 |
| Rabeprazole Sodium 1.0 mg/kg | 0.2 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -1.3 |
| Rabeprazole Sodium 1.0 mg/kg | -1.0 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -2.9 |
| Rabeprazole Sodium 1.0 mg/kg | -1.4 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -11.5 |
| Rabeprazole Sodium 1.0 mg/kg | -8.5 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 78 |
| Rabeprazole Sodium 1.0 mg/kg | 83 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 92 |
| Rabeprazole Sodium 1.0 mg/kg | 88 |
8 reviews available for rabeprazole and Esophagitis, Peptic
| Article | Year |
|---|---|
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; | 2022 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inh | 2016 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; | 2006 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh | 2002 |
31 trials available for rabeprazole and Esophagitis, Peptic
| Article | Year |
|---|---|
Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Topics: Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Endosco | 2018 |
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es | 2013 |
A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Female; Humans; Japan; Male; Middle Aged | 2014 |
Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Topics: Aged; Esophageal and Gastric Varices; Esophageal pH Monitoring; Esophagitis, Peptic; Famotidine; Fem | 2013 |
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anxiety; Cytochrome P-450 CYP2C19; Depression; Dos | 2015 |
Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Endoscopy, Gastroin | 2010 |
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid | 2010 |
Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Dose-Response Relationship, Dru | 2011 |
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2011 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P | 2011 |
Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; | 2012 |
Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2012 |
Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Bioma | 2013 |
[Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chronic Disease; Epithel | 2002 |
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esophagitis, Pe | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2004 |
[A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disord | 2005 |
[A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2006 |
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hyd | 2006 |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hyd | 2007 |
Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studie | 1997 |
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2000 |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2000 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis | 2002 |
Integrated acidity and rabeprazole pharmacology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2002 |
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Benzimidazoles; Dyspepsia; Enzyme Inhibi | 2002 |
[Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Epith | 2002 |
21 other studies available for rabeprazole and Esophagitis, Peptic
| Article | Year |
|---|---|
Effects of mosapride combined with rabeprazole on symptom scores and inflammatory factors in elderly patients with reflux esophagitis.
Topics: Aged; Benzamides; Esophagitis, Peptic; Humans; Morpholines; Rabeprazole | 2023 |
Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.
Topics: Aged; Chronic Disease; Dose-Response Relationship, Drug; Esophagitis, Peptic; Female; Humans; Male; | 2017 |
Acid burn or cytokine sizzle in the pathogenesis of heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Esophagus; Female; Gastroesophageal Re | 2013 |
Significant increase of esophageal mucin secretion in patients with reflux esophagitis after healing with rabeprazole: its esophagoprotective potential.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Pe | 2009 |
[The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Pe | 2009 |
Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Endoscopy; Esophagitis, Peptic; Female; Gastric Fundu | 2010 |
Patients vote with their feet for 'On demand' rabeprazole in the maintenance treatment phase of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Health Care Costs; | 2010 |
Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Pe | 2011 |
Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Claudin-1; Claudin-3; Claudin-4; Disease Models, A | 2011 |
Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Body Mass Index; Esophagitis, Pept | 2012 |
Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Humans; Mal | 2012 |
Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cohort Studies; Esophagitis, Pepti | 2012 |
[A case of the successful treatment of the esophageal leukoplakia with rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Esophageal Neoplasms; Esophagitis, Pe | 2002 |
[The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
[Reflux esophagitis. Step-down instead of step-up].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Eso | 2006 |
Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost Sav | 2007 |
Use of proton pump inhibitors may cause squamous epithelial masking of intramucosal carcinoma in Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Barrett Esophagus; Biopsy; Diagnostic | 2007 |
Case of paroxysmal atrial fibrillation improved after the administration of proton pump inhibitor for associated reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Atrial Fibrillation; Enzyme Inhibitors; Esophagitis, Peptic | 2007 |
Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Trees; Drug | 2000 |
Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Tec | 2000 |
Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Tec | 2001 |